Professor Matt Stevenson
PhD (Lancaster), BSc (Lancaster)
Population Health, School of Medicine and Population Health
Professor of Health Technology Assessment
m.d.stevenson@sheffield.ac.uk
+44 114 222 0691
+44 114 222 0691
+44 114 222 0749
(Fax)
Regent Court (ScHARR)
Full contact details
Professor Matt Stevenson
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91直播
S1 4DA
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91直播
S1 4DA
- Profile
-
I graduated with a PhD in Operational Research from Lancaster University. I am a Member of NICE Technology Appraisal Committee C and the NICE Diagnostic Advisory Committee. I have led numerous projects for NICE and the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC). I am the Director of ScHARR-TAG.
- Research interests
-
Discrete event simulation, individual patient modelling and mathematical modelling within health technology assessment.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Value in Health.
- . Health Technology Assessment, 25(39).
- . Health Technology Assessment, 25(21), 1-68.
- . The Lancet, 392(10156), 1403-1412.
- . PLoS ONE, 13(10), e0205013-e0205013.
- . PharmacoEconomics.
- . PharmacoEconomics.
- . Journal of Rheumatology, 44(7), 973-980.
- . Value in Health, 20(1), 141-151.
- . Health Technology Assessment, 20(78), 1-406.
- . Health Technology Assessment, 20(46), 1-246.
- . Health Technology Assessment, 20(35), 1-610.
- . Health Technol Assess, 18(17), 1-290.
- . Chest, 141(2 SUPPL.), e351S-e418S.
- . BMC Cancer, 11.
- . Br J Surg, 96(10), 1147-1156.
- . Health Technol Assess, 13(45), iii-134.
- . MED DECIS MAKING, 28(5), 650-667.
- . Health Econ, 16(10), 1009-1023.
- . Health Technol Assess, 11(4), 1-134.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. HEALTH TECHNOL ASSES, 11(7), 1-+.
- Accurate, practical and cost-effective assessment of carotid stenosis in the UK. HEALTH TECHNOL ASSES, 10(30), 1-+.
- . Health Technology Assessment, 10(15).
- . Health Technol Assess, 9(22), 1-160.
- . Med Decis Making, 24(1), 89-100.
- . Health Technol Assess, 6(29), 1-146.
All publications
Journal articles
- . PharmacoEconomics.
- . RMD Open, 10(1), e003980-e003980.
- . Neuromuscular Disorders, 34, 61-67.
- . British Journal of Dermatology, ljad430.
- . eClinicalMedicine, 64, 102213-102213.
- . Health Technology Assessment, 27(14).
- . BMJ, 381, e074678.
- A REVIEW OF EXTERNAL EVIDENCE USED TO SUPPORT SURVIVAL EXTRAPOLATION IN ASSESSMENTS OF CANCER DRUGS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). VALUE IN HEALTH, 25(12), S340-S340.
- . Clinical Journal of the American Society of Nephrology, 17(3), 385-394.
- . Journal of Medical Economics, 1-28.
- . Health technology assessment (Winchester, England), 25(76), 1-228.
- . BMC Medical Research Methodology, 21(1).
- . Addiction.
- . Health Technology Assessment, 25(59), 1-224.
- . npj Digital Medicine, 4.
- . Value in Health.
- . Health Technology Assessment, 25(39).
- . Value in Health.
- . Journal of Medical Economics, 24(1), 363-372.
- . Health Technology Assessment, 25(21), 1-68.
- . Frontiers in Public Health, 8.
- . Health Technology Assessment, 24(11), 1-150.
- . The Lancet Infectious Diseases, 20(1), e2-e10.
- . Cost Effectiveness and Resource Allocation, 18(1).
- . Journal of Managed Care & Specialty Pharmacy, 25(12), 1300-1306.
- . Medical Decision Making, 39(7), 867-878.
- . Medical Decision Making.
- . International Journal of Technology Assessment in Health Care.
- . BJOG: An International Journal of Obstetrics & Gynaecology, 126(3), 383-392.
- . Health Technology Assessment, 22(66), 1-294.
- . The Lancet, 392(10156), 1403-1412.
- . PLoS ONE, 13(10), e0205013-e0205013.
- . Pharmacoeconomics.
- . PharmacoEconomics.
- . PharmacoEconomics, 36, 769-778.
- . Pharmacoeconomics, 36(12), 1427-1437.
- . Applied Health Economics and Health Policy.
- . Health Technology Assessment, 22(20).
- . PharmacoEconomics, 36(9), 1063-1072.
- . PharmacoEconomics, 36(7), 759-768.
- . PharmacoEconomics, 36(8), 903-915.
- . Health Technology Assessment, 21(71), 1-258.
- . PharmacoEconomics, 35(11), 1141-1151.
- . PharmacoEconomics.
- . PharmacoEconomics, 35(10), 1103-1109.
- . Pharmacoeconomics.
- . Journal of Rheumatology, 44(7), 973-980.
- . Lancet.
- . BMJ Open, 7(6), e015414-e015414.
- . BMJ Open, 7(1).
- . Value in Health, 20(1), 141-151.
- . BMJ Open.
- . Health Technology Assessment, 20(35), 611-614.
- . PharmacoEconomics, 35(4), 415-424.
- . Health Technology Assessment, 20(78), 1-406.
- . PharmacoEconomics, 34(12), 1241-1253.
- . PharmacoEconomics, 34(7), 673-680.
- . Health Technology Assessment, 20(46), 1-246.
- . Health Technology Assessment, 20(37), 1-414.
- . Health Technology Assessment, 20(35), 1-610.
- . PharmacoEconomics, 34(5), 463-477.
- . BMC Psychiatry, 15.
- . PharmacoEconomics, 33(8), 833-847.
- . BMC Psychiatry, 15(1).
- . Journal of the Intensive Care Society, 16(1), 24-30.
- . Current Rheumatology Reports, 16(10).
- . PharmacoEconomics, 32(10), 1029-1029.
- Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
- . Pharmacoeconomics, 32(8), 735-743.
- . International Journal of Systems Science, 45(1), 60-68.
- . Health Technol Assess, 18(33), 1-120.
- . Health Technol Assess, 18(10), 1-252.
- . Health Technol Assess, 18(16), 1-176.
- . Health Technol Assess, 18(17), 1-290.
- . Pharmacoeconomics, 31(11), 981-990.
- . PharmacoEconomics - Italian Research Articles, 15(2), 91-100.
- . Health Technol Assess, 17(48), i-141.
- . Arch Dis Child, 98(12), 939-944.
- . British Journal of Surgery, 100(9), 1180-1188.
- . Health Technol Assess, 17(36), 1-vi.
- . Pharmacoeconomics, 31(6), 479-488.
- . Pharmacoeconomics, 31(8), 653-661.
- . Pharmacoeconomics, 31(6), 471-478.
- . Pharmacoeconomics, 30(12), 1119-1132.
- . Clinical Oncology, 24(10).
- . Health Technol Assess, 16(37), 1-iv.
- . Heart, 98(20), 1498-1503.
- . Health Technol Assess, 16(5), iii-195.
- . Chest, 141(2 SUPPL.), e351S-e418S.
- Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 16(4), 1-174.
- . PharmacoEconomics - Italian Research Articles, 14(1), 47-54.
- . PharmacoEconomics, 30(1), 35-46.
- . Injury, 43(9), 1423-1431.
- . Eur J Prev Cardiol, 19(3), 474-483.
- Hemiarthroplasty and total hip arthroplasty for treating primary intracapsular fracture of the hip: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 15(36), 1-74.
- . Value Health, 14(6), 953-960.
- The cost-effectiveness of diagnostic management strategies for adults with minor head injury. Injury.
- . Health Technol Assess, 15(27), 1-202.
- . Value Health, 14(4), 465-474.
- . Health Technol Assess, 15 Suppl 1, 69-75.
- . Health Technol Assess, 15(36), 1-74.
- . BMC Cancer, 11.
- . Journal of Urology, 186(2), 534-535.
- . Pharmacoeconomics, 29(2), 133-140.
- . Med Decis Making, 31(1), 43-52.
- . Health technology assessment (Winchester, England), 14(Suppl. 2), 47-53.
- . Health Technol Assess, 14(47), 1-iv.
- . Health Technol Assess, 14(44), 1-iv.
- . Health Technol Assess, 14(30), 1-iv.
- . Health Technol Assess, 14 Suppl 1, 63-67.
- . Value Health, 13(5), 580-584.
- A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism.. J. Simulation, 4, 14-23.
- . Health technology assessment (Winchester, England), 14(Suppl. 2), 55-62.
- . Value Health, 13(2), 215-221.
- . STROKE, 40(11), 3511-3517.
- . Health Technol Assess, 13(56), 1-iii.
- . Med Decis Making, 29(6), 678-689.
- . HEALTH TECHNOL ASSES, 13, 55-60.
- . HEALTH TECHNOL ASSES, 13, 37-42.
- . HEALTH TECHNOL ASSES, 13, 43-48.
- . Br J Surg, 96(10), 1147-1156.
- Vitamin K to prevent fractures in older women: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(45).
- . Health Technol Assess, 13(45), iii-134.
- . Value Health, 12(8), 1100-1105.
- . J OPER RES SOC, 60(4), 506-518.
- . British Journal of Surgery, 96(S1), 15-15.
- . Health Technol Assess, 13(2), iii-91.
- . MED DECIS MAKING, 28(5), 650-667.
- . Bone, 43(1), 214-214.
- . J BONE MINER METAB, 26(1), 34-41.
- . Health Econ, 16(10), 1009-1023.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
- . Health Technol Assess, 11(4), 1-134.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. HEALTH TECHNOL ASSES, 11(7), 1-+.
- Optimal algorithm for evaluating suspected DVT. Journal of Family Practice, 55(9), 754.
- Accurate, practical and cost-effective assessment of carotid stenosis in the UK. HEALTH TECHNOL ASSES, 10(30), 1-+.
- . QJM, 99(6), 377-388.
- Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.. Health technology assessment (Winchester, England), 10(15).
- . Health Technology Assessment, 10(15).
- . Women's Health Medicine, 3(4), 149-151.
- Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J OPER RES SOC, 56(2), 214-221.
- . Health Technol Assess, 9(22), 1-160.
- . Med Decis Making, 24(1), 89-100.
- . Vaccine, 20(13-14), 1778-1786.
- Treatment of established osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 6(29), 1-146.
- The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 6(5).
- . Health Technol Assess, 6(29), 1-146.
- . Injury, 32(4), 267-274.
- . Health Technology Assessment, 1-93.
- . Medical Decision Making.
- . Journal of the Intensive Care Society, 175114372311691-175114372311691.
- . Medical Decision Making, 0272989X2211076-0272989X2211076.
- . Health Technology Assessment, 20(78), 407-424.
- . Health Technology Assessment, 15(Suppl 1), 69-75.
- . Health Technology Assessment, 14(Suppl 2), 47-53.
- . Health Technology Assessment, 14(Suppl 1), 63-67.
- . Health Technology Assessment, 13(Suppl 3), 43-48.
- . Health Technology Assessment, 13(Suppl 3), 37-42.
- . SN Comprehensive Clinical Medicine.
- . Health Technology Assessment, 20(1), 1-198.
- . Health Technology Assessment, 19(18), 1-120.
Chapters
Conference proceedings papers
- Use Of Real-World Data In Cost-effectiveness Analysis Of Sequential Biologic Treatment For Rheumatoid Arthritis. MEDICAL DECISION MAKING, Vol. 44(2) (pp NP49-NP50)
- USE OF REAL-WORLD DATA IN COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS. VALUE IN HEALTH, Vol. 25(12) (pp S373-S374)
- The economic burden of hemophilia B - a lifetime decision analytic model. HAEMOPHILIA, Vol. 26 (pp 111-111)
- GENE THERAPY FOR PEOPLE WITH HAEMOPHILIA B (PWHB): DEVELOPMENT OF A COST-EFFECTIVENESS MODEL FRAMEWORK. HAEMOPHILIA, Vol. 26 (pp 107-107)
- COMPARING THE SENSITIVITY OF PATIENT-LEVEL DISCRETE EVENT SIMULATION AND COHORT HEALTH-STATE TRANSITION MODELLING FRAMEWORKS IN THE ADVENT OF NOVEL THERAPIES FOR PEOPLE WITH SEVERE HAEMOPHILIA A. HAEMOPHILIA, Vol. 26 (pp 65-66)
- . Value in Health, Vol. 22(Supplement 3) (pp S819-S819). Copenhagen, Denmark, 2 November 2019 - 2 November 2019.
- . Value in Health, Vol. 22(S3) (pp S522-S522). Copenhagen, Denmark, 2 November 2019 - 2 November 2019.
- . Value in Health, Vol. 22(Suppl 3) (pp S821-S821). Copenhagen, Denmark, 2 November 2019 - 2 November 2019.
- . Value in Health, Vol. 22 (pp S337-S338)
- Key findings from an expert validation workshop to establish an appropriate modelling framework in severe haemophilia A. HAEMOPHILIA, Vol. 25 (pp 182-183)
- . HAEMOPHILIA, Vol. 25 (pp 66-67)
- . Emergency Medicine Journal, Vol. 34(12) (pp A867-A868)
- . Value in Health, Vol. 20(9) (pp A746-A746)
- . Oral Presentations
- THE CLINICAL AND COST-EFFECTIVENESS OF DIFFERENT MATERNAL SYPHILIS SCREENING STRATEGIES IN BRAZIL. VALUE IN HEALTH, Vol. 20(9) (pp A572-A572)
- COST-EFFECTIVENESS ANALYSIS OF SELEXIPAG VERSUS INHALED ILOPROST IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SWEDEN. VALUE IN HEALTH, Vol. 19(7) (pp A556-A556), 29 October 2016 - 2 November 2016.
- . Journal of Reproductive and Infant Psychology, Vol. 33(3) (pp E3-E4), 13 September 2016 - 14 September 2016.
- . Value in Health, Vol. 18(7) (pp A343-A343)
- . Value in Health, Vol. 17(7) (pp A458-A459)
- . Value in Health, Vol. 17(7) (pp A584-A584)
- . Emergency Medicine Journal, Vol. 31(9) (pp 775.2-775)
- . Emergency Medicine Journal, Vol. 31(9) (pp 775.1-775)
- . Value in Health, Vol. 17(7) (pp A380-A380)
- . VALUE IN HEALTH, Vol. 16(7) (pp A615-A616)
- . VALUE IN HEALTH, Vol. 16(7) (pp A587-A587)
- . VALUE IN HEALTH, Vol. 16(7) (pp A565-A565)
- . GUT, Vol. 61 (pp A203-A203)
- Full-color active-matrix quantum dot light emitting device displays. Proceedings of the International Display Workshops, Vol. 2 (pp 1181-1184)
- . VALUE IN HEALTH, Vol. 14(7) (pp A541-A541)
- . VALUE IN HEALTH, Vol. 14(7) (pp A445-A445)
- COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND-A DISCRETE EVENT SIMULATION MODELLING. VALUE HEALTH, Vol. 12(7) (pp A335-A335)
- Cost-effectiveness of bosentan versus epoprostenol and no active treatment when added to palliative care for UK patients with pulmonary arterial hypertension of WHO functional class III. EUROPEAN HEART JOURNAL, Vol. 29 (pp 859-859)
- Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event. VALUE HEALTH, Vol. 11(3) (pp A194-A195)
- Bosentan is a cost-effective treatment for united kingdom patients with pulmonary arterial hypertension of WHO class III. VALUE HEALTH, Vol. 11(3) (pp A197-A197)
- The cost-effectiveness of calcium and vitamin D in women with low dietary calcium intake. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S39-S40)
- The cost-effectiveness of bisphosphonates, raloxifene and teriparatide in women with a prior fracture, low BMD and replete of calcium and vitamin D. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S39-S39)
- Should we treat TIA as a medical emergency?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 75(8) (pp 1217-1217)
- The cost-effectiveness of bisphosphonates, raloxifene and hormone replacement therapy in women with established osteoporosis and replete of calcium and vitamin D. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S111-S111)
- The cost-effectiveness of calcium and vitamin D supplementation in women with low dietary intake of these nutrients and at risk of osteoporosis. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S87-S88)
- Cost-effectiveness of current treatments for established female osteoporosis. OSTEOPOROSIS INT, Vol. 11 (pp S11-S11)
Reports
- Explaining national differences in the mortality of Covid-19 : individual patient simulation model to investigate the effects of testing policy and other factors on apparent mortality
Posters
- PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
- Addressing challenges in the conduct of a systematic review of clinical prediction models in rheumatoid arthritis. 25th Cochrane Colloquium, Edingurgh.
- Clinical prediction models for patients with early rheumatoid arthritis: A systematic review and evidence synthesis. MEMTAM (Methods for Evaluation of medical prediction Models, Test And Biomarkers), Utecht, The Nethe.
- A Framework for the Economic Evaluation of Sequential Therapies for Chronic Conditions (2014).
- Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK.
- Ultrasound to Guide Treatment Decisions in Rheumatoid Arthritis.
- Cost effectiveness of group art therapy for patients with non-psychotic mental health disorders in England and Wales (2014).
- The cost-effectiveness of non-invasive liver tests for the detection of liver fibrosis in patients with suspected alcohol-related liver disease.
Other
Preprints
- Research group
-
PhD students:
- Ben Kearns
- Ash Bullement
- Teaching interests
-
- I am co-module leader for the advanced simulation module on the Health Economic and Decision Science MSc
- I am an active PhD supervisor
- Professional activities and memberships
-
- I am a Member of NICE Appraisal Committee C
- I am a Member of NICE Diagnostic Advisory Committee
- I am a Member of the Centre for Bayesian Statistics in Health Economics